Ventra Sciences Review 2026: A- Supplier, Reviewed Samples, COAs, and Catalog Notes

Ventra Sciences is a US research-peptide vendor that appears to have launched in early 2026, but it does not look like a throwaway new storefront. PepPal reviewed Ventra samples and found the product presentation, labeling, packaging, and QR-linked COA flow to be cleaner than most newly listed vendors in this segment.

That is why Ventra now earns an A- and the #4 spot in PepPal's supplier rankings. The only reason the grade stops at A- is track record: as of June 2026, PepPal has not found Janoshik, Finnrick, or comparable independent aggregate testing for Ventra, and the brand has not had much time to build a long public review history. If that independent testing appears, this grade could move higher.

Ventra Sciences is an online research-peptide store operating at ventrasciences.com. Its published pages carry 2026 dates, and the catalog and COA library were populated in early 2026, so the brand reads as a recent launch rather than an established vendor. That newness is the main caveat. The actual presentation PepPal reviewed is strong for a young supplier: clean labels, professional packaging, organized product imagery, and a COA-first site structure.

The brand positions itself around the tagline "Proof Over Promises," emphasizing per-vial COA access and third-party testing. One differentiator versus typical vendors is a multi-peptide spray-format line, which Ventra markets alongside standard lyophilized vials. The site also advertises cold-chain shipping and free shipping over $200.

Business-identity transparency is the one area where the public site still feels thinner than the product presentation. PepPal did not find a public physical address, named ownership, or a published support phone number on Ventra's site; the listed contact method is email only. That does not erase the strong sample review, but it is one reason Ventra sits at A- instead of A or A+.

Ventra's stated quality workflow is QR-code-per-vial linked to a batch COA, with HPLC for purity, mass spectrometry for identity, and a sterility panel. The FAQ states all peptides are verified at 99%+ purity through independent third-party HPLC testing, with COAs available per product and batch. The workflow is well organized and matched the documentation-forward positioning PepPal saw in sample review.

The public COA library is partial. On Ventra's COA page, some products show a direct "View COA" link (for example, BPC-157, GHK-Cu, Tesamorelin, Selank, the GLOW and KLOW blends, and the coded GLP products), while many others show "Request COA," which routes to an email request rather than a one-click document. So the marketing line that every vial ships with a QR-linked COA is not yet matched by a fully public, browsable COA set for every SKU.

The remaining gap is independent aggregate testing. As of June 2026, PepPal found no Janoshik, Finnrick, or comparable public testing dataset for Ventra. That is the main reason the grade is A- rather than higher. The vendor presentation is strong; the public third-party testing record just needs time to catch up.

Ventra carries a fairly broad catalog organized into vendor-defined categories such as recovery, metabolic, cognitive, longevity, endocrine, pigmentation, and supplies. Listed compounds include BPC-157, TB-500, a BPC-157/TB-500 blend, GHK-Cu, the GLOW (GHK-Cu/BPC-157/TB-500) and KLOW (adds KPV) blends, CJC-1295 (with and without DAC), Ipamorelin, Sermorelin, Tesamorelin, IGF-1 LR3, MOTS-C, NAD+, Epitalon, Selank, Semax, PT-141, Melanotan II, Cagrilintide, and bacteriostatic/amino water.

Like several grey-market vendors, Ventra uses coded names for GLP-class compounds rather than branded drug names: GLP-1-S, GLP-2-T, GLP-3-R, and a c-Amylin/GLP-1 listing. Readers comparing the underlying compounds should match by the code and the COA rather than assuming a brand name.

The spray-format listings are the catalog's clearest point of differentiation; most comparable vendors focus on lyophilized vials only. Confirm format, concentration, and the matching COA on each product page before sourcing.

Representative homepage prices include CJC-1295 + Ipamorelin at $70, MOTS-C (10 mg) at $55, NAD+ (500 mg) at $95, and Selank (5 mg) at $34. These sit in a typical mid-market range for US research vendors, but Ventra does not publish a full transparent price grid the way some larger catalogs do, so confirm current pricing per SKU at checkout.

Ventra advertises free shipping on orders over $200 and a newsletter sign-up offer of 15% off. The PepPal partner discount runs through the SAVE10 link. Treat any discount as conditional and confirm it appears in the order summary before completing checkout.

Ventra's FAQ states it ships within the United States only, using USPS and UPS, with same-day handling for orders placed before 12 PM CST and typical delivery in 2-5 business days. The homepage separately markets "2-day cold-chain shipping." Those two claims are not identical, so readers comparing fulfillment timelines should confirm the actual service level at checkout.

Orders are described as shipping in discreet, unmarked packaging with insulation and cold packs when needed. International shipping is not offered at this time.

Support is email-based, with a stated 4-8 business-hour response window. PepPal did not find a published phone line, live chat, or community channel for Ventra, which is a narrower support footprint than some established vendors offer.

The PepPal partner discount for Ventra is delivered through the SAVE10 partner link. The link is set up to apply the partner offer, but the exact amount and any exclusions should be confirmed in the order summary before completing payment. Ventra also lists a separate 15% newsletter sign-up discount.

Ventra's reviewed samples and COA workflow are strong enough for an A- grade today. The remaining gaps are mostly about time and independent corroboration, not poor presentation.

For broader market context, see the PepPal supplier directory and the grey-market supplier comparison guide. The right pick depends on whether you prioritize a verified track record or are comparing a newer documentation-forward vendor.